Introduction {#S0001}
============

Ovarian cancer (OC) is the seventh leading cancer diagnosis and the fifth leading cause of cancer-related mortality.[@CIT0001] The American Cancer Society estimated that in 2018, 22,240 new cases will be diagnosed, with 14,070 deaths.[@CIT0002] OC represents the 8th most common cancer in Kuwait among Kuwaitis and non-Kuwaitis.[@CIT0003] Epithelial ovarian cancer (EOC) is the most common type of OC; serous tumors are the most common subtype.[@CIT0004]

*BRCA1/2* are important tumor suppressor genes implicated in DNA double-strand break repair by homologous recombination (HR), which is also involved in cellular proliferation and chromosomal stability.[@CIT0005]

The association between germline mutations in *BRCA1* and *BRCA2* and the risk of developing OC is well established. The lifetime prevalence rates of OC are estimated to be 28--66% for individuals with *BRCA1* mutations and 16--27% for those with *BRCA2* mutations.[@CIT0006]

Variation in the worldwide prevalence of *BRCA1* and *BRCA2* mutations is well recognized. The prevalence of germline *BRCA1* and *BRCA2* mutations in individuals with EOC varies from 5% to 20%, and somatic mutations occur less frequently (2% and 8%, respectively).[@CIT0007]--[@CIT0009]

*BRCA* mutations are associated with longer survival rates after OC diagnosis and a favorable response to platinum-based therapy, with an overall improved prognosis.[@CIT0010]

In our region, there is a paucity of data about the proportion of OC patients carrying these mutations; these data would improve genetic screening and counseling for women with OC. In Kuwait, this is the 1st study discussing the prevalence of BRCA1/2 mutation in ovarian cancer patients.

In the current study, we recruited prospectively women diagnosed with OC were prospectively studied to assess the *BRCA1* and *BRCA2* mutation frequencies, with a focus on the clinical characteristics of mutation carriers compared to non-carriers and an exploration of the outcomes of treatment.

Patients and methods {#S0002}
====================

Women aged 18 to 75 years who were diagnosed with EOC were eligible for the study. A total of 104 patients were recruited; 64 (61.54%) were of Arab origin, 34 (32.69%) were Asian, 4 (3.85%) were European, and 2 (1.92%) were African. The study was approved by the ethical committee of the Ministry of Health (Kuwait) with the number 295/2015 on 18/10/2015. All patients received an explanation of the nature of the study and signed a detailed informed consent form. At the time of their entry into the study, a complete personal and family history, including a detailed history of relatives diagnosed with cancer (age at diagnosis, site of cancer), was taken and recorded. All patients were subjected to full clinical examinations; laboratory tests (complete blood work, liver function tests, kidney function tests, and CA125 level assessment); baseline CT scans of the chest, abdomen, and pelvis; and pathological examinations by an expert gynecological pathologist.

Eligible patients provided a 20-mL blood sample. Samples were sent within 72 hrs to Myriad Genetics.

The genetic analysis consisted of sequencing all the translated exons and immediately adjacent intronic regions of the *BRCA1* and *BRCA2* genes, as well as large rearrangement analysis (MLPA) of all the *BRCA1* (OMIM 113705/GenBank entry U14680) and *BRCA2* (OMIM 600185/GenBank entry U43746) exons.

The mutations reported were checked in linked Database of Single Nucleotide Polymorphisms (dbSNP), ClinVar databases, BRCA Exchange, LOVD, and Associated regional and university pathologists (ARUP).[@CIT0011]--[@CIT0015]

The variants were classified based on the American Society of Medical Genetics and Genomics (ACMG) into 1) Class 5 (pathogenic), Class 4 (likely pathogenic), Class 3 (variant of uncertain significance), class2 (likely benign), and Class 1(benign).[@CIT0016]

Details regarding the chemotherapy treatments (neoadjuvant, adjuvant, first line, and subsequent lines of chemotherapy) were recorded. Details of the surgeries were also recorded. Assessment included measurement of the level of CA125 and CT scans of the chest, abdomen, and pelvis. The date of first progression was determined based on the CA125 level and confirmed by imaging according to the response evaluation criteria in solid tumor guidelines (RECIST criteria). The median duration of follow-up was 39.75 months (95% CI 25.18--54.33).

Statistical methods {#S0003}
===================

The statistical analyses were performed with SPSS version 22. Categorical data were summarized using percentages; numerical data were summarized as the means and standard deviations or medians and ranges. Chi-square tests and Fisher's exact tests were used to examine the relationships between qualitative variables. The survival analysis was performed using the Kaplan--Meier method. A log-rank test was used to compare the survival curves. All tests of hypotheses were conducted at an alpha level of 0.05, with a 95% confidence interval.

The median duration of follow-up was estimated using the reverse Kaplan--Meier method. PFS was defined as the interval from histological diagnosis to the date of first progression or last follow-up. OS was defined as the interval from histological diagnosis to the date of death or last follow-up.

Results {#S0004}
=======

Pathogenic *BRCA1* and *2* mutations were detected in 22 patients (21.15%). *BRCA1* in 15 patients (17.05%) and *BRCA 2* in 7 patients (7.95%). On analyzing the frequency of *BRCA* mutation based on ancestry, we found that out of the 64 Arab patients, 14 (21.9%) were carriers for a pathogenic *BRCA* mutation, and out of the 34 patients of Asian origin, 8 (23.5%) were *BRCA* carriers, none of the patients from European or African origin carried the mutation. Only one mutation occurred twice. Among the 21 detected mutations, 19 were pathogenic, 1 was of uncertain significance, and 1 was benign. Fifteen mutations were Frameshifts, two were missense, two nonsense, and 2 were splice-site. Two Novel *BRCA 1* mutations were detected; c.4658del which is predicted to result in the premature truncation of the BRCA 1 protein at position 1558 (p.Leu1553Cysfs\*6) and c.3919del which is predicted to result in the premature truncation of the BRCA1 protein at amino acid position 1317 (p.Thr1307Leufs\*11).

The age at diagnosis was a strong predictor of the presence of a pathogenic *BRCA1/2* mutation; out of the 22 patients carrying the mutation, 19 were younger than 50 years (86.4%). Compared with patients with no family history of cancer, patients with a family history of cancer had a significantly higher incidence of *BRCA* mutations (*P*=0.005). Approximately 72% of the patients with pathogenic *BRCA* mutations were diagnosed with tumors at an advanced stage. Compared with women diagnosed with other histologies, those diagnosed with high-grade serous tumors had a higher incidence of pathogenic mutations (*P*=0.07). The relationships between patient characteristics and *BRCA 1/2* carrier status are listed in [Table 1](#T0001){ref-type="table"}. The locations of the *BRCA* gene mutations are listed in [Table 2](#T0002){ref-type="table"}.Table 1Patient characteristicsPatient characteristicsNegative for *BRCA1/2* mutations N=(82) %Positive for *BRCA1/2* mutations N=(22) %*P*-value**Age at diagnosis***51.81±11.0049.32±11.53*0.76**Age groups**0.04 \>5037(66.07)19(33.92) ≥5045(93.75)3(6.25)**Ancestry**0.63 Arab50(78.1%)14(21.9%) Asian26(76.5%)8(23.5%) European4(100%)0 African2(100%)0**Family history**0.005 Yes22(56.4)17(43.6) No60(92.3)5(7.7)**Personal breast cancer history**0.46 No77(79.4)20(20.6) Yes5(71.4)2(28.6)**Figo stage**0.05 I24(88.9)3(11.1) II12(80)3(20) III38(70.4)16(29.6) IV8(100)00**Pathological subtype**65170.07 Serous55(74.3)19(25.7) Clear cell2(100)0(0) Endometrioid14(93.33)1(6.67) Others11(84.6)2(15.4) Table 2Location of BRCA gene mutationsGeneExon/intronVariationAA ChangeVariant effectAncestryAgeClassFrequencyPreviously reported*BRCA1*Exon 11c.1140dupG*p*.Lys381Glufs\*3Frame ShiftAsian5051Yes*BRCA1*Exon 8c.512dupT*p*.Gin172Thrfs\*10Frame ShiftAsian4451Yes*BRCA1*Intron 17c.5074+1G\>ASplice siteAsian4751Yes*BRCA1*Exon 11c.2719G\>T*p*.GIu907\*NonsenseAsian4551Yes*BRCA1*Exon 11c.3607C\>T*p*.Arg1203\*NonsenseArab4751Yes*BRCA1*Intron 7c.441+1G\>ASplice siteArab4552Yes*BRCA1*Exon 17c.5030_5033del 4*p*.Thr1677IIefs\*2Frame ShiftAsian4551Yes*BRCA1*Exon 20c.5229_5230del AA*p*.Arg1744Lysfs\*Frame ShiftArab3851Yes*BRCA1*Exon 11c.4065_4068del 4*p*.Asn1355Lysfs\*Frame ShiftArab4651Yes*BRCA1*Exon 11c.2679_2682del GA*p*.Lys893Asnfs\*106Frame ShiftArab4451Yes*BRCA1*Exon 11c.3919del*p*.Thr1307Leufs\*11Frame ShiftArab3551Novel*BRCA1*Exon 15c.4658del*p*.Leu1553Cysfs\*6Frame ShiftArab4751Novel*BRCA1*Exon 2185delAG*p*.Leu22-Glu23LeuValfsFrame ShiftArab3451Yes*BRCA1*Exon 11c.3548A\>G*p*.Lys1183ArgMissenseArab4611Yes*BRCA 2*Exon 11c.4631del*p*.Asn1544Thrfs\*24Frame ShiftArab4451Yes*BRCA 2*Exon 23c.9019A\>TpArg3007\*MissenseArab6931Yes*BRCA 2*Exon 11c.4570_4573del 4phe1524IIefs\*18Frame ShiftAsian4651Yes*BRCA 2*Exon 11c.4631delApAsn1544Thrfs\*24Frame ShiftAsian5651Yes*BRCA 2*Exon 11c.4415-4418delAGAA*p*.Lys1472ThrfsFrame ShiftArab4351Yes*BRCA 2*Exon 11c.4859delA*p*.Asn1544ThrfsFrame ShiftAsian3651Yes*BRCA 2*Exon 11c.3971del T*p*.Leu1324GlnfsFrame ShiftArab4851Yes[^1][^2]

The details of the primary treatments received by all patients are listed in [Table 3](#T0003){ref-type="table"}. The response to neoadjuvant chemotherapy was high (93.9%). All patients underwent surgery, which was optimal in approximately three-fourths of the patients. In total, 85.6% of the patients received adjuvant chemotherapy.Table 3Primary treatment receivedPrimary treatment receivedN=104Neoadjuvant chemotherapyN%No. of patients33(31.7%)Chemotherapy regimenPaclitaxel/carboplatinMedian no. of cycles4(3--6)Responsive to neoadjuvant therapy33CR1(3%)\*PR30(90.9%)\*SD1(3%)\*PD1(3%)\*Surgery104(100%)Optimal76(73.1%)Suboptimal28(26.9%)Adjuvant chemotherapyNo. of patients89(85.6%)Chemotherapy regimenPaclitaxel/carboplatinAvastin added15(14.4%)Median no. of chemotherapy cycles3(3--4)Median no. of avastin cycles8(4--12)[^3][^4]

After primary treatment, 47 patients (45.2%) relapsed. Thirty-seven patients (78.7%) relapsed locally and 10 (21.3%) developed visceral metastases. ([Table 4](#T0004){ref-type="table"}) Compared with non-carriers, *BRCA* mutation carriers experienced visceral metastasis more often (*P*=0.01) ([Table 5](#T0005){ref-type="table"}).Table 4Pattern of relapse and treatment received at relapsen%Relapsed patients47(45.2%)Site of relapseLocal37(78.7%)Distant10(21.3%)Platinum sensitivitySensitive39(82.98%)Resistant8(17.02%)Chemotherapy regimenPaclitaxel/carboplatin35(74.47%)Gemcitaben/carboplatin4(8.51%)Caelyx8(17.02%)Avastin added11(23.4)Median no. of chemotherapy cycles6(3--9)Median no. of avastin cycles12(4--45)ResponseCR8(17%)PR30(63.8%)SD3(6.4%)DP6(12.8%)[^5] Table 5Association of relapse pattern with BRCA1/2 mutation statusNegative for *BRCA1/2* mutations N=(38) %Positive for *BRCA1/2* mutations N=(9) %*P*-value**Sensitivity to platinum-based chemotherapy after primary therapy**0.59 Sensitive31(79.49)8(20.5) Resistant7(87.5)1(12.5)**Site of relapse**0.01 Local recurrence33(89.2)4(10.8) Distant metastasis5(50)5(50)**Response to second-line therapy**0.12 CR + PR29(76.3%)9(23.7%) SD + PD9(100%)0(0%)

Patients with relapse-free intervals greater than 6 months were considered platinum sensitive. In this cohort, 39 (82.98%) relapsed patients were platinum sensitive. The *BRCA* mutation status did not appear to affect the pattern of platinum sensitivity at the time of relapse (*P*=0.59). Details of the treatments received at the time of relapse are shown in [Table 4](#T0004){ref-type="table"}.

Patients carrying pathogenic *BRCA1/2* mutations had a median PFS of 42.43 months (95% CI 32.04--52.83), which was longer than the median PFS of 22.24 months (95% CI 14.83--29.58) in non-carriers; this difference approached significance (*P*=0.08) ([Figure 1](#F0001){ref-type="fig"}).Figure 1Relationship of overall survival with BRCA1/2 mutation status.

BRCA1/2 mutations were predictors of longer OS times; patients with mutations had a median OS of 64.32 months (95% CI 38.09--90.06), while non-carriers had a median OS of 56.63 months (95% CI 50.05--63.21) (*P*=0.04) ([Figure 2](#F0002){ref-type="fig"}).Figure 2Relationship of relapse free survival with BRCA1/2 mutation status.

The results of the univariate analysis showing the association of tumor characteristics with PFS and OS are shown in [Tables 6](#T0006){ref-type="table"} and [7](#T0007){ref-type="table"}.Table 6Univariate analysis for the association of tumor characteristics with progression-free survivalProgression-free survivalMedian, months(95% CI)*P*-value**BRCA1/2 mutation status**0.08 Negative22.24(14.83--29.58) Positive42.43(32.04--52.83)**Pathological subtype**0.47 Serous28.19(12.05--44.33) Others26.35(7.33--45.37)**Stage**\>0.001 INR\* IINR\* III20.66(11.99--29.35) IV14.44(2.3--29.23)**Surgery**\>0.001 Optimal42.43(29.46--55.4) Suboptimal16.05(12.16--19.94)[^6] Table 7Univariate analysis for the association of tumor characteristics with overall survivalOverall survivalMedian, months(95% CI)*P*-value**BRCA1/2 mutation status**0.04 Negative56.63(50.05--63.21) Positive64.32(38.09--90.06)**Pathological subtype**0.87 Serous64.32(53.29--73.36) OthersNR**Stage**\>0.001 INR IINR III59.72(51.34--67.89) IV39.53(8.43--70.63)**Surgery**\>0.001 OptimalNR Suboptimal45.6(34.1--57.1)[^7]

In the multivariate analysis, only an early stage at diagnosis and optimal debulking were predictors of longer PFS and OS.

Discussion {#S0005}
==========

This prospective observational cohort study was performed on all patients with non-mucinous OC, either newly presenting to a medical oncology outpatient clinic or old under follow-up. The aim of this study was to determine the prevalence of germline *BRCA* mutations in OC patients and their correlation with clinical outcomes.

Pathogenic *BRCA1/2* mutations were found in 22 patients (21.15%). *BRCA1* mutations were detected in 15 patients (68.2%), and *BRCA 2* mutations were found in 7 (31.8%). This was consistent with the overall incidence rate of 22.5% reported by Safra T et al, with 16.8% carrying *BRCA1* mutations and 5.8% carrying *BRCA2* mutations.[@CIT0017] Alsop K found pathogenic *BRCA1/2* mutations in 14.1% of the patients enrolled in his trial, and more than half of the mutations were in *BRCA1*.[@CIT0018] Other studies found lower incidence rates of *BRCA 1/2* mutations, ranging from 8% to 13%.[@CIT0019],[@CIT0020] In a study performed by Alhuqail A et al in the King Faisal Specialist Hospital and Research Centre, 19 of 65 OC patients (29.2%) had *BRCA 1/2* mutations. Sixteen of the 65 OC patients (24.6%) had *BRCA1* mutations, while the remaining 3 patients (4.6%) had *BRCA2* mutations.[@CIT0021] This prevalence of *BRCA* mutations in patients with OC is higher than that identified in this study.

If we exclude the high prevalence of *BRCA 1/2* mutations in one study of Ashkenazi Jews (AJs), most of the studies found comparable prevalence rates of *BRCA 1/2* mutations of approximately 13--15% in OC patients in African, Asian, white, and Hispanic populations.[@CIT0022] In the Arab population, the available data are not conclusive. The slightly higher prevalence of *BRCA 1/2* mutations observed in this region compared to other regions may be attributed to the tradition of consanguineous marriages, which increase the rate of genetic and congenital abnormalities.

In this series, the age of the patients at presentation was a strong predictor of the presence of a pathogenic *BRCA1/2* mutation; 86.4% of the patients carrying mutations were diagnosed before the age of 50. Helpman L reported a mean age of 44±5 years for patients carrying *BRCA1/2* mutations in his cohort, Jaya M found that most of the patients carrying *BRCA1/2* mutations were younger than 50 years, and SoonKhoo U et al reported an average age of 53 years among patients with *BRCA1/2* mutations. Safara T et al reported a higher median age of 58 years among patients with *S* mutations.[@CIT0023]--[@CIT0026]

In a study by Safra T that explored the prevalence of *BRCA* mutations in ethnically diverse groups, more than half of the *BRCA* carriers (59.1%) were of AJ descent. Other *BRCA1/2* mutation carriers were non-AJ, non-Jewish Caucasian, African American, Hispanic, and unknown.[@CIT0017] The mutation prevalence among African--Americans with strong histories of breast cancer and OC was 16.3% in *BRCA1* and 11.3--14.4% in *BRCA2*.[@CIT0026] Hispanic patients with strong family histories of cancer had mutation prevalence rates of 15.7--22.7% in *BRCA1* and 6--8% in *BRCA2*.[@CIT0027]

In this series, the incidence rates of *BRCA1/2* mutations were 21.9% in patients from the Middle East and 23.5% in patients from Asia. The prevalence of *BRCA* mutations in this cohort was close to that found in Hispanic populations, lower than that identified in African American populations, and substantially lower than that observed in AJ populations.[@CIT0017]

In this study, 43.6% of the patients with a family history of cancer carried a *BRCA* mutation, while patients with no family history of cancer had an incidence rate of *BRCA1/2* mutations of 7.7%; the difference was significant (*P*=0.005). This finding was consistent with those reported by Helpman L et al, Alsop K et al, and Menkiszk J et al, who found that 63%, 43.5%, and 38.7% of the patients with *BRCA* mutations, respectively, had a family history of breast or OC.[@CIT0018],[@CIT0023],[@CIT0028] Many factors may contribute to this finding, including the accuracy of the history collected, patient ethnicity, and patient selection.[@CIT0018],[@CIT0029],[@CIT0030] In most of the published data, family history has an important impact on an individual's risk of cancer. This may emphasize the importance of testing for *BRCA1/2* mutations based on family history.

Approximately three-fourths of the patients with *BRCA1/2* mutations in this study presented with an advanced stage of OC; a similar finding was reported by J. Liu et al, with 75% of the *BRCA1* mutation carriers and 67.3% of the *BRCA2* mutation carriers diagnosed at stage 3 or 4. Alsop K et al also found that women with pathogenic mutations were diagnosed with tumors at an advanced stage.[@CIT0018],[@CIT0031] In a study performed by Alhuqail A et al in the King Faisal Specialist Hospital and Research Centre, 90% of the OC patients harboring pathogenic *BRCA* mutations were diagnosed with advanced-stage serous carcinomas.[@CIT0021]

In this series, pathogenic *BRCA1/2* mutations were detected in 86.3% of the patients with high-grade serous carcinoma (HGSC). This finding was consistent with the results of other reports by Alsop K, Malander S, and Fong PC.[@CIT0018],[@CIT0032],[@CIT0033] These results support the routine testing for *BRCA1/2* mutations in all patients with non-mucinous OC, especially HGSC.

Compared with non-carriers, *BRCA1/2* mutation carriers experience a better response to platinum-based chemotherapy and a longer PFS;[@CIT0018],[@CIT0034]--[@CIT0036] however, this conclusion is not consistent across all studies, as some other trials reported no effect of *BRCA* mutation status on response to chemotherapy, PFS, or OS.[@CIT0031],[@CIT0037] This heterogeneity in terms of the outcome can be explained by the effect of other prognostic factors, such as optimal surgery and age.[@CIT0038]

The mechanism by which *BRCA* mutations sensitize tumor cells to chemotherapy is well known. However, it is not clear how this sensitization translates into a survival.[@CIT0039] Data on survival (PFS and OS) were found to be inconsistent in a recent meta-analysis.

Zhong et al reported longer OS and PFS in patients carrying *BRCA1/2* mutations than in non-carriers.[@CIT0040]

Xu et al reported the same findings, and another meta-analysis analyzing the results of 34 studies showed a favorable effect of *BRCA* mutation on OS (HR 0.69; 95% CI 0.6--0.79, *P*\>0.002). Eighteen of those studies reported a longer PFS in patients with *BRCA1/2* mutations (HR 0.69; 95% CI 0.63--0.67, *P*=0.118).[@CIT0041] In this study, patients with pathogenic *BRCA1/2* mutations had median PFS of 42.43 months, which was longer than the PFS of 22.24 months observed in non-carriers; the difference approached significance (*P*=0.08). Additionally, compared with non-carriers, *BRCA1/2* mutation carriers had longer OS times (64.32 months and 56.63 months, respectively) (*P*=0.04).

In multivariate analysis, stage at diagnosis and optimal cytoreductive surgery were the only independent predictors of both PFS and OS. These findings were consistent with those in previous reports by Kathryn Alsop et al, Limor Helpman, and others.[@CIT0005],[@CIT0018],[@CIT0023]

In conclusion, this study reveals that the overall frequency of *BRCA* germline mutations (both pathogenic and likely pathogenic mutations) in OC patients is high. We believe that these results have significant implications for the development of preventive strategies and the use of effective targeted treatments, such as PARP inhibitors, in women affected by OC.

Conclusion {#S0006}
==========

We documented a number of pathogenic *BRCA1* and *2* mutations in this patients cohort, two novel mutations were detected.

The importance of *BRCA* mutations in the assessment of prognosis and prediction of survival in OC patients is clear; therefore, it is important to include the *BRCA1/2* mutation status in the stratification of patients and the design of future clinical trials.
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[^1]: **Notes:** \*Class (ACMG): 1=benign. 2=likely benign. 3=mutation of uncertain significance. 4=likely pathogenic. 5=pathogenic.

[^2]: **Abbreviations:** AA Change, Amino Acid Change; ACMG, American College of Medical Genetics and Genomics.

[^3]: **Note:** \*Percent of cases receiving neoadjuvant therapy.

[^4]: **Abbreviations:** CR, complete remission; PR, partial remission; SD, stationary disease; DP, disease progression.

[^5]: **Abbreviations:** CR, complete remission; PR, partial remission; SD, stationary disease; DP, disease progression.

[^6]: **Abbreviation:** NR, not reached.

[^7]: **Abbreviation:** NR, not reached.
